Denali Therapeutics Sells Rare Pediatric Disease Voucher for $195 Million

By Bobby Samwell • Thursday, June 18 13:04 • Permanent Link

Denali Therapeutics said June 18 it entered into a definitive agreement to sell its rare pediatric disease priority review voucher for gross proceeds of $195 million.

The voucher was awarded after the FDA’s accelerated approval in March 2026 of Avlayah, Denali’s enzyme replacement therapy for Hunter syndrome. Denali said the sale will add cash to support its TransportVehicle-enabled pipeline across lysosomal storage disorders and neurodegenerative diseases.

The company highlighted a broad slate of programs that could benefit from the proceeds. Its clinical-stage portfolio includes DNL126 for Sanfilippo syndrome type A, DNL593 for GRN-related frontotemporal dementia, DNL952 for Pompe disease and DNL628 for Alzheimer’s disease.

Denali also listed several programs in IND-enabling development: DNL921 for Alzheimer’s disease, DNL111 for Parkinson’s disease and Gaucher disease, DNL622 for Hurler syndrome and DNL422 for Parkinson’s disease.

The voucher transaction remains subject to customary closing conditions, including the expiration of the Hart-Scott-Rodino waiting period. As a result of these announcements, the company's shares have moved 0.19% on the market, and are now trading at a price of $23.535. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.